Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver ...
BURLINGTON, Mass.-- (BUSINESS WIRE)-- PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics ...
PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25 th Conference of the Asian ...
PharmaEssentia and AOP Orphan Announce Completion of Recruitment of Pivotal Phase III Trial PROUD-PV
- PharmaEssentia and AOP Orphan announce completion of recruitment of the pivotal European Phase III trial PROUD-PV (www.proud-pv.com) to support global marketing of P1101 (Ropeginterferon alfa-2b).
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
AOP Orphan Pharmaceuticals AG (AOP Orphan) has announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood disorder after reviewing encouraging results from a phase 3 study. In the ...
The Reserve Bank of New Zealand will leave interest rates unchanged on July 9, a majority of economists polled by Reuters expected, with the median forecast showing just one more 25 basis point cut ...
BURLINGTON, Mass., January 07, 2025--(BUSINESS WIRE)--Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results